AST-120 to Target Protein-Bound Uremic Toxins Improves Cardiac Output and Kidney Oxygenation in Experimental Chronic Kidney Disease
Kidney and Blood Pressure Research · 2023
DOI: 10.1159/000529272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2023. Verfasst von Ebba Sivertsson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Uremia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Chronic kidney disease (CKD) is a global health problem with increasing incidence which is closely associated with cardiac dysfunction. In CKD, uremic toxins accumulate as kidney function declines. Additionally, high salt intake is a growing health issue worldwide which can exacerbate kidney disease. In this study, we investigated the effect of reducing plasma levels of protein-bound uremic toxins in a rat model of CKD, challenged with high salt intake and compared the effects to those of conventional treatment using an angiotensin-converting enzyme inhibitor (ACEI).
Methods
In rats, the right kidney and 2/3 of the left kidney were surgically removed (5/6 nephrectomy). Animals were fed a normal-salt diet and randomized to either no treatment (control) or chronic treatment with either the oral absorbent AST-120 to reduce plasma levels of protein-bound uremic toxins or the ACEI enalapril to inhibit angiotensin II signaling for 5 weeks. Following treatment, kidney function was measured before and after a week of high salt intake. Cardiac output and markers of oxidative stress were measured at the end of the study period.
Results
Treatment with AST-120 resulted in decreased levels of the uremic toxin indoxyl sulfate, improved cardiac output (mL/min: AST-120 44.9 ± 5.4 compared to control 26.6 ± 2.0; p < 0.05), and decreased urinary oxidative stress. ACEI reduced oxidative stress in kidney tissue and improved the glomerular filtration rate in response to high salt intake (mL/min: ACEI 1.5 ± 0.1; compared to control 1.1 ± 0.1; p < 0.05). Both interventions improved intrarenal oxygen availability (mm Hg: AST-120 42.8 ± 0.8; ACEI 43.2 ± 1.9; compared to control 33.4 ± 1.3; p < 0.05).
Conclusion
AST-120 administered to reduce plasma levels of uremic toxins, such as indoxyl sulfate, has potential beneficial effects on both cardiac and kidney function. Targeting uremic toxins and angiotensin II signaling simultaneously could be an efficient strategy to target both cardiac and kidney dysfunction in CKD, to further slow progression of disease in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
- Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan.
Zitieren
APA
Sivertsson, E., Ceder, S., Nangaku, M., Hansell, P., Nordquist, L., & Palm, F. (2023). AST-120 to Target Protein-Bound Uremic Toxins Improves Cardiac Output and Kidney Oxygenation in Experimental Chronic Kidney Disease. Kidney and Blood Pressure Research. https://doi.org/10.1159/000529272
Vancouver
Sivertsson E, Ceder S, Nangaku M, Hansell P, Nordquist L, Palm F. AST-120 to Target Protein-Bound Uremic Toxins Improves Cardiac Output and Kidney Oxygenation in Experimental Chronic Kidney Disease. Kidney and Blood Pressure Research. 2023. doi:10.1159/000529272
BibTeX
@article{Sivertsson2023,
author = {Sivertsson, Ebba and Ceder, Sara and Nangaku, Masaomi and Hansell, Peter and Nordquist, Lina and Palm, Fredrik},
title = {AST-120 to Target Protein-Bound Uremic Toxins Improves Cardiac Output and Kidney Oxygenation in Experimental Chronic Kidney Disease},
journal = {Kidney and Blood Pressure Research},
year = {2023},
doi = {10.1159/000529272}
}
EUVIMED